Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationPractice MgmtIssue 666

Good or Bad News for Medicare Diabetes Patients?

Medicare and Medicaid competitive bidding may result in limited options….

Advertisement

After successfully piloting the first round in nine regions, the Centers for Medicare and Medicaid Services (CMS) will expand the competitive bidding program for durable medical equipment (DME) and mail-order programs across the nation starting in July. In the first round, the program brought down the cost for certain supplies an average of 45 percent for Medicare patients.

The cost of diabetes supplies such as blood glucose meter, test strips, and lancets are expected to be reduced an average of 72 percent through a national mail-order program. According to CMS, "The Medicare program will save $25.7 billion and beneficiaries will save $17.1 billion between 2013 and 2022."

However, not everyone is happy with the new program. The DME industry, including manufacturers, suppliers and providers of medical equipment, believe that the new program "is offering fewer and lowest-cost products" which will substantially discourage providers from offering brand name or more advanced products.

The agency has used real-time monitoring data that showed very few beneficiary complaints and no negative impact on beneficiary health status compared with non-competitive bidding areas. The program will continue to expand under close monitoring.

“We will continue to monitor the program closely as it expands to ensure the same success we saw in the program last year, with beneficiaries continuing to have access to all the services they need, while paying a much lower price,” said Jonathan Blum, deputy CMS administrator and director of CMS’ Center for Medicare.

CMS Feb 21, 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 28 February, 2013 and appeared in  MedicationPractice MgmtIssue 666

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Second Tuberculosis Vaccine Treatment for Type 1 Diabetes Underway
Posted June 19, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Aaron Vinik, MD

Category: General Diabetes
Credits: 1.25